Published Date : Feb 29, 2016
Albany, New York, Feb 29, 2016: Keratoconjunctivitis sicca is a condition that arises when the eye is not able to produce enough tears or any tears produced evaporate quickly. The condition occurs among humans but is also observed to affect some animals. It is due to these attributes of the condition that it is also referred to as the dry eye syndrome (DES). Medical practitioners say that this is the most common type of eye disease, with prevalence rising in postmenopausal women and the elderly. Being a disease with such a widespread prevalence, there is a correspondingly high demand for drugs and therapies to treat the dry eye syndrome. A new report that is now available on the website of MarketResearchReports.biz, titled ‘PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment To 2024,’ studies this market in detail. The report will help readers track sales of dry eye syndrome therapeutics worldwide during the period from 2014-2024.
People suffering from this condition may experience signs and symptoms such as gritty eye irritation, dryness, burning, and stringy discharge from the eye. As a result, patients are likely to suffer from problems such as tear film instability, ocular discomfort, and visual disturbances. If not treated in time, the condition can cause considerable damage to the ocular surface.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/564712
While the demand for therapeutics to treat dry eye syndrome continues to remain steady, there has been little activity in the market by way of new therapeutics launches over the last ten years. Overall, the availability of treatment options has not kept pace with the increase in demand. Japan is an exception with the launch of two therapies – Diquas (2010) and Mucosta (2013) – which were launched on the market.
The report states that the dearth of treatment options will soon be addressed with the launch of new drugs that are in the pipeline. The new DES drugs will be launched during the forecast period of the report and will drive the market for dry eye syndrome drugs in the nine major markets of the world. Already, the launch of drugs such as Ikervis in Europe in 2015 has begun to change the shape of this market. Moreover, market approvals have been sought for Restasis and Diquas in other countries. These developments will induce growth in the dry eye syndrome drugs market.
Population aging will be yet another massive driver for the dry eye syndrome market; these epidemiological changes will spur the demand for drugs and therapies to treat the dry eye syndrome. The report further investigates which unmet needs exist in the market and makes recommendations to players for the monetization of the same.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org